Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD

Oral ruxolitinib is approved to treat aGvHD and cGvHD, while ruxolitinib cream is approved for atopic dermatitis and vitiligo. Topical corticosteroids are the mainstay of skin-directed therapy but may incompletely treat cutaneous cGvHD.We conducted a phase 2 prospective, randomized, double-blind trial evaluating the efficacy and safety of ruxolitinib 1.5% cream in patients ≥12 years old with cutaneous nonsclerotic and superficially sclerotic cGvHD with ≥2% of body surface area (BSA) affected. Patients were eligible if any systemic therapy was stable for ≥4 weeks and concurrent topical/photo- therapy was not used.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Alina Markova, Esperanza B. Papadopoulos, Stephen Dusza, Veronica Rotemberg, Jelena Ostojic, Rizi Ai, Tara Maier, Mario E. Lacouture, Roni Tamari, Boglarka Gyurkocza, Brian C. Shaffer, Michael Scordo, Miguel-Angel Perales, Andrew C. Harris, Doris M. Ponce Tags: 1 Source Type: research